128 related articles for article (PubMed ID: 31060855)
1. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
[TBL] [Abstract][Full Text] [Related]
2. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
Khunger A; Khunger M; Velcheti V
Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
[TBL] [Abstract][Full Text] [Related]
3. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
[No Abstract] [Full Text] [Related]
5. A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening.
Lung J; Hung MS; Lin YC; Jiang YY; Fang YH; Lu MS; Hsieh CC; Wang CS; Kuan FC; Lu CH; Chen PT; Lin CM; Chou YL; Lin CK; Yang TM; Chen FF; Lin PY; Hsieh MJ; Tsai YH
Sci Rep; 2020 Oct; 10(1):16943. PubMed ID: 33037234
[TBL] [Abstract][Full Text] [Related]
6. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
[TBL] [Abstract][Full Text] [Related]
7. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
Jiang L; Yang P; Liu Y; Li J
J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
[TBL] [Abstract][Full Text] [Related]
8. Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma.
Ichikawa K; Ohno S; Kubo S; Nakajima H
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719253
[TBL] [Abstract][Full Text] [Related]
9. Combined BRAF, EGFR, and MEK Inhibition in Patients with
Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
[TBL] [Abstract][Full Text] [Related]
11. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
[TBL] [Abstract][Full Text] [Related]
12. Characterization of
Watanabe H; Inoue Y; Karayama M; Yazawa S; Mochizuka Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Shinmura K; Inui N; Suda T
JCO Precis Oncol; 2024 Apr; 8():e2300538. PubMed ID: 38662982
[TBL] [Abstract][Full Text] [Related]
13. Targeting
Baik CS; Myall NJ; Wakelee HA
Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
[TBL] [Abstract][Full Text] [Related]
14. SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring
Choi YJ; Chung YH; Lee K; Jeong M; Ko SG
Anticancer Res; 2024 May; 44(5):1905-1913. PubMed ID: 38677764
[TBL] [Abstract][Full Text] [Related]
15. Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.
Inoue T; Kunimasa K; Tamiya M; Kawamura T; Minami T; Nishino K
Thorac Cancer; 2024 Apr; 15(11):929-933. PubMed ID: 38429896
[TBL] [Abstract][Full Text] [Related]
16. Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.
Falkman L; Sundin A; Skogseid B; Botling J; Bernardo Y; Wallin G; Zhang L; Welin S; Lase I; Mollazadegan K; Crona J
Ups J Med Sci; 2024; 129():. PubMed ID: 38716076
[TBL] [Abstract][Full Text] [Related]
17. A large-scale, multicenter characterization of BRAF G469V/A-mutant non-small cell lung cancer.
Wu H; Feng J; Lu S; Huang J
Cancer Med; 2024 May; 13(10):e7305. PubMed ID: 38770647
[TBL] [Abstract][Full Text] [Related]
18. BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ; van den Eertwegh AJM; Haanen JB; van Rijn RS; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JWWB; Hospers GAP; Kapiteijn E; Bloem M; Piersma D; Stevense-den Boer M; Verheijden RJ; van der Veldt AAM; Wouters MWJM; Blokx WAM; Suijkerbuijk KPM
Cancer; 2024 May; 130(9):1673-1683. PubMed ID: 38198485
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.
Priantti JN; Rodrigues NMV; de Moraes FCA; da Costa AG; Jezini DL; Heckmann MIO
Endocrine; 2024 May; ():. PubMed ID: 38709445
[TBL] [Abstract][Full Text] [Related]
20. Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With
Fusco MJ; Piña Y; Macaulay RJ; Sahebjam S; Forsyth PA; Peguero E; Walko CM
Cancer Control; 2021; 28():10732748211040013. PubMed ID: 34620004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
